Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Gilead Buys Kite, The Future Of CAR-T, And A Visit To The New Whole Foods

Published 09/01/2017, 12:48 AM
Updated 07/09/2023, 06:31 AM
GILD
-
AAPL
-
AMZN
-
NVS
-
BLUE
-
KITE
-
SB9
-

  • (0:35) - Hurricane Harvey and North Korea Tensions
  • (2:30) - Gilead's Acquisition of Kite Pharma: What Is CAR-T Therapy?
  • (4:45) - Novartis CAR-T Cell Therapy Receives Approval By FDA
  • (6:50) - CAR-T Biotech Stocks On The Rise
  • (10:40) - Is This A New Era For Biotech?
  • (15:15) - Price Cutting On Whole Foods Products
  • (19:20) - Amazon Echoes and Instacart Indirect Competition
  • (23:45) - Upcoming Rewards Program For Prime Members
  • (26:00) - Episode Roundup: Podcast@Zacks.com

On today’s episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week’s biggest stories, including Gilead’s acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon’s changes to Whole Foods stores.

Make sure to subscribe and leave the show a rating on iTunes!

It was a busy week in the biotech sector, so Maddy and Ryan welcomed an expert guest, Brad Loncar, to recap the latest major events. Brad is the creator of the Loncar Cancer Immunotherapy Index, which tracks the combined performance of several major companies that are developing therapies to treat cancer by harnessing the body’s own immune system.

This makes Brad the perfect person to discuss the Gilead’s (NASDAQ:GILD) massive $11.9 billion takeover of Kite Pharma (NASDAQ:KITE) , as well as the milestone of Novartis’ (NYSE:NVS) CAR-T cancer therapy. Maddy and Ryan also asked Brad about the impact that these events have had on other CAR-T develops, such as Juno Therapeutics (NASDAQ:JUNO) and Bluebird Bio (NASDAQ:BLUE) , and Brad shared some key info that every bio tech investor needs to know right now.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Finally, Maddy and Ryan also discussed their recent trip to a Whole Foods WFM store to investigate the changes made by Amazon (NASDAQ:AMZN) this week. Make sure to tune in to the show to hear their reactions, and check out some pictures from the visit below:


As a reminder, if you feel that we missed something, or if you want us to cover a different story, shoot us an email at podcast@zacks.com. Make sure to check out all of our other audio content at zacks.com/podcast, and remember to subscribe and leave us a rating on iTunes.

As always, thanks for listening to this episode of the Zacks Friday Finish Line, and check back for even more news from the investment and financial world!

Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>



Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Kite Pharma, Inc. (KITE): Free Stock Analysis Report

bluebird bio, Inc. (BLUE): Free Stock Analysis Report

Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.